PainChek® enters home care market through pain management collaboration with MPS Connect

HIGHLIGHTS

- PainChek enters the Australian Home Care market, establishing an integrated pain management solution with Sigma Healthcare subsidiary MPS Connect
- The integrated PainChek® Universal Solution to be launched Q1 2022 within MPS Connect's MediSphere™ Medication Management System
- MPS Connect currently services over 800 preferred pharmacy clients and 1400 Residential Aged care facilities in Australia

PainChek® Ltd (ASX: PCK) ("PainChek®" or "the Company"), developer of the world's first smart phone-based pain assessment and monitoring application, is pleased to announce that is has entered the Australian Home Care market, establishing an integrated pain management solution with MPS Connect, a leading Australian medication services company.

The companies have collaborated to integrate the PainChek® Universal Solution into the soon to be launched MediSphere™ Medication Management System. The system combines pain assessment and pain treatment into one novel software system. The goal is to ensure the right medication is delivered, based on accurate pain assessment, for people living at home with home care packages.

This collaboration will bring together the pain medication expertise of MPS Connect (a subsidiary of Sigma Healthcare) and the pain assessment device from PainChek to monitor the effect of the intervention, creating a unique pain treatment and monitoring programme for people living at home.

In the agreement the PainChek™ Universal App is fully integrated into the MPS Connect MediSphere™ system to enhance the user experience and health outcomes for residents, nurses and patients. MPS Connect currently services over 800 preferred pharmacy clients and 1400 Residential Aged care facilities.

There are over 235,000 Federal Government funded Home Care packages in Australia, the majority of which are managed by Residential Aged Care providers. MPS Connect has a broad range of pharmaceutical supply agreements with aged care facilities and community pharmacies through existing business agreements and its parent company Sigma Healthcare.

MPS Connect Head of Healthcare Operations Renee Watson said:

"We are delighted to integrate the PainChek solution into MediSphere™, creating an integrated pain assessment and medication management solution for our home-based consumers. We are already a major supplier of pain medication in Australia and this collaboration further elevates our offering to that of a total pain management solution. Our initial target clients are the home care providers, but we see opportunities to extend the partnership into broader home consumer markets in line with the increasing demand for home care."

ABN 21 146 035 127   **P:** +61 8 9388 8290
401, 35 Lime Street,   **E:** info@painchek.com
Sydney, NSW, 2000   **W:** painchek.com

PainChek Limited (ASX: PCK) | PG 1

PainChek CEO Phillip Daffas said:

"This is a significant milestone in our home care strategy. The MPS MediSphere™ solution is innovative and the integration of PainChek into its medication management suite ensures all home consumers can receive best practice pain and medication management. PainChek Universal was developed specifically to ensure we had a pain assessment solution that also meets the needs of the global aged care, home care, hospital and disability markets. This is another example of how we build innovative partnerships to access new high value markets for PainChek."

The PainChek Universal system is now fully integrated into the MPS MediSphere™ system and is being distributed under standard PainChek commercial terms by MPS Connect to both Australian home care and aged care clients as of Q1 2022.

Home Care is a large, growing global market and is financially supported by governments worldwide to enable this strategic shift for the elderly.

This release has been authorized for release by CEO Philip Daffas.

For more information:

Sally McDow
Company Secretary, PainChek
sally.mcdow@boardroomlimited.com.au
0420 213 035

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About MPS Connect

MPS Connect has more than 20 years' experience in medication management. Today, we specialise in providing end to end medication management solutions to the aged care industry in two ways. The first is our MPS Medica medication management software that connects GPs to pharmacists to aged care facilities, their care staff and residents. It saves time, minimises documentation and reduces preventable medications incidents. The second is MPS Pak - the safe, accurate and timely solution to medication disbursement. We pack and distribute over sixty million medication packettes for more than 800 aged care homes and community pharmacies around the country. Whether you're prescribing, dispensing or administering medication, MPS Connect makes the entire process easier and safer. MPS Connect - delivering better health outcomes for Australia's ageing.

To find out more visit, https://mpsconnect.com.au/

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere.

PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

ABN 21 146 035 127   **P:** +61 8 9388 8290
401, 35 Lime Street,   **E:** info@painchek.com
Sydney, NSW, 2000   **W:** painchek.com

PainChek Limited (ASX: PCK) | PG 2

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who have not yet learnt to speak. Both the adult and infants products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com

ABN 21 146 035 127   **P:** +61 8 9388 8290
401, 35 Lime Street,   **E:** info@painchek.com
Sydney, NSW, 2000   **W:** painchek.com

PainChek Limited (ASX: PCK) | PG 3